Skip to content

A clinical trial of Ayurveda formulations in COVID-19

Effect of Malla Chandrodaya & Ashtadashang ghan vati in Patients with mild to moderate Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026229
Enrollment
100
Registered
2020-06-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Combination of Malla Chandrodaya & Ashthadashang Ghana vati with anupana of Parijata Swaras.: Malla Chandrodayaa 32 mg & Ashtadashang Ghana Vati 500 mg twice daily with anupana of Parij

Sponsors

Dr Namrata Joshi
Lead Sponsor
Dr Abhishek Pandey
Collaborator
Dr Jaya Chakravarty
Collaborator
Dr Kamal Nayan Dwivedi
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: i. Laboratory-confirmed mild to moderate symptomatic cases of COVID-19 above between 18years irrespective of sex will be included. ii. Patients able to take medicines orally. iii. Patients willing to provide signed informed consent may be included in the Inclusion criteria.

Exclusion criteria

Exclusion criteria: i. Cases of severe vomiting which would affect oral administration of medicine difficult. ii. Cases of respiratory failure and requiring mechanical ventilation iii. Combined organ failure requiring ICU monitoring. iv. Any other condition, which as per the investigator would jeopardize the outcome of the trial.

Design outcomes

Primary

MeasureTime frame
1. All-cause mortality 2. WHO Ordinal Scale for Clinical Improvement of COVID-19Timepoint: Daily until discharge

Secondary

MeasureTime frame
1. Virological clearance of nasopharyngeal samples 2. Admission to critical care unit 3. Need for supplemental oxygen, mechanical ventilation/oxygenation or ECLS 4. Need for intravenous vasoactive medications 5. Need for renal replacement therapy 6. Hospital-free days,ICU-free daysTimepoint: Outcome 1-Day 3, 5, 8, 11 (all ± 1 day) if hospitalized Outcome 2 to 6-Daily until hospital discharge,

Countries

India

Contacts

Public ContactDr Namrata Joshi

BHU

drnamratajoshi@gmail.com9319037367

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026